The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
Open accessAbstract
Purpose: To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone. Methods: A committee of investigators experienced in conducting trials for prostate cancer defined new consensus criteria by reviewing previous criteria, Response Evaluation Criteria in Solid Tumors (RECIST), and emerging trial data. Results: The Prostate Cancer Clinical Trials Working Group (PCWG2) recommends a two-objective paradigm: (1) controlling, relieving, or eliminating disease manifestations that are present when treatment is initiated and (2) preventing or delaying disease manifestations expected to occur. Prostate cancers progressing despite castrate levels of testosterone are considered castration resistant and not hormone refractory. Eligibility is defined using standard disease assessments to authenticate disease progression, prior treatment, distinct clinical subtypes, and predictive models. Outcomes are reported independently for prostate-specific antigen (PSA), imaging, and clinical measures, avoiding grouped categorizations such as complete or partial response. In most trials, early changes in PSA and/or pain are not acted on without other evidence of disease progression, and treatment should be continued for at least 12 weeks to ensure adequate drug exposure. Bone scans are reported as “new lesions” or “no new lesions,” changes in soft-tissue disease assessed by RECIST, and pain using validated scales. Defining eligibility for prevent/delay end points requires attention to estimated event frequency and/or random assignment to a control group. Conclusion: PCWG2 recommends increasing emphasis on time-to-event end points (ie, failure to progress) as decision aids in proceeding from phase II to phase III trials. Recommendations will evolve as data are generated on the utility of intermediate end points to predict clinical benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 2×
“The demonstration of a survival benefit in a phase III trial and a confirmatory trial(7) led to the approval of docetaxel in 2004.(6) Since then, clinical trials for patients with castrate metastatic disease are being designed in three contexts: before receiving treatment with docetaxel, with agents in combination wit…”
BackgroundSelf-citationPetrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Self-citationU.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, & U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-79 · Cited by 2,856
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Self-citationBubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W. D., Freidlin, B., Halabi, S., Hudes, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3461 · Cited by 977
Self-citationBilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391504 · Cited by 859
Self-citationThe Androgen Axis in Recurrent Prostate Cancer
Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1146-03 · Cited by 675
Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer
Halabi, S., Small, E. J., Kantoff, P. W., Kattan, M. W., Kaplan, E. B., Dawson, N. A., Levine, E. G., Blumenstein, B. A., & Vogelzang, N. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.100 · Cited by 674
Self-citationHolzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L., Ryan, C., Smith, S., Scher, H., Scardino, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63112-4 · Cited by 577 · cited 1×
“Sources include the adrenal glands or the tumor itself as a result of the upregulation of the genes involved in androgen synthesis.(15,16) Recognizing that some patients have higher testosterone levels despite continued androgen depletion with GnRH analog therapy, and that total testosterone levels do not reflect bioa…”
BackgroundSelf-citation
Cited by
Items 101–122 of 122
Schweizer, M. T., Antonarakis, E. S., Wang, H., Ajiboye, A. S., Spitz, A., Cao, H., Luo, J., Haffner, M. C., Yegnasubramanian, S., Carducci, M. A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010563 · Cited by 254
Self-citationCastration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets
Chi, K. N., Bjartell, A., Dearnaley, D., Saad, F., Schröder, F. H., Sternberg, C., Tombal, B., & Visakorpi, T. (2009) · European Urology · doi:10.1016/j.eururo.2009.06.027 · Cited by 253
Self-citationSubudhi, S. K., Aparicio, A., Gao, J., Zurita, A. J., Araujo, J. C., Logothetis, C. J., Tahir, S. A., Korivi, B. R., Slack, R. S., Vence, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611421113 · Cited by 226
Sathekge, M. M., Lawal, I. O., Bal, C., Bruchertseifer, F., Ballal, S., Cardaci, G., Davis, C., Eiber, M., Hekimsoy, T., Knoesen, O., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00638-1 · Cited by 210
Pond, G. R., Sonpavde, G., de Wit, R., Eisenberger, M. A., Tannock, I. F., & Armstrong, A. J. (2014) · European Urology · doi:10.1016/j.eururo.2013.09.024 · Cited by 193
Self-citationAntonarakis, E. S., Heath, E. I., Smith, D. C., Rathkopf, D., Blackford, A. L., Danila, D. C., King, S., Frost, A., Ajiboye, A. S., Zhao, M., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-314 · Cited by 180
Self-citationHummel, H.-D., Kufer, P., Grüllich, C., Seggewiss-Bernhardt, R., Deschler-Baier, B., Chatterjee, M., Goebeler, M.-E., Miller, K., de Santis, M., Loidl, W., et al. (2021) · Immunotherapy · doi:10.2217/imt-2020-0256 · Cited by 154
Vesper, H. W., Bhasin, S., Wang, C., Tai, S. S., Dodge, L. A., Singh, R. J., Nelson, J., Ohorodnik, S., Clarke, N. J., Salameh, W. A., et al. (2009) · Steroids · doi:10.1016/j.steroids.2009.01.004 · Cited by 152
Badrising, S., van der Noort, V., van Oort, I. M., van den Berg, H. P., Los, M., Hamberg, P., Coenen, J. L., van den Eertwegh, A. J. M., de Jong, I. J., Kerver, E. D., et al. (2014) · Cancer · doi:10.1002/cncr.28518 · Cited by 136
Steroid biosynthesis and prostate cancer
Sharifi, N., & Auchus, R. J. (2012) · Steroids · doi:10.1016/j.steroids.2012.03.015 · Cited by 116
Molina, A., & Belldegrun, A. (2011) · Journal of Urology · doi:10.1016/j.juro.2010.10.042 · Cited by 112
Danila, D. C., Szmulewitz, R. Z., Vaishampayan, U., Higano, C. S., Baron, A. D., Gilbert, H. N., Brunstein, F., Milojic-Blair, M., Wang, B., Kabbarah, O., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00646 · Cited by 90
Self-citationAnnala, M., Fu, S., Bacon, J. V. W., Sipola, J., Iqbal, N., Ferrario, C., Ong, M., Wadhwa, D., Hotte, S. J., Lo, G., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.205 · Cited by 73
Saad, F., Shore, N., Van Poppel, H., Rathkopf, D. E., Smith, M. R., de Bono, J. S., Logothetis, C. J., de Souza, P., Fizazi, K., Mulders, P. F. A., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.04.032 · Cited by 63
Self-citationLavaud, P., Gravis, G., Foulon, S., Joly, F., Oudard, S., Priou, F., Latorzeff, I., Mourey, L., Soulié, M., Delva, R., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.09.022 · Cited by 63
“We defined radiological progression according to PCWG2 criteria [19] as the date when a minimum of two new bone lesions on a bone scan or a body scan are observed, or progression according to RECIST 1.”
MethodDeveloping biomarker-specific end points in lung cancer clinical trials
Neal, J. W., Gainor, J. F., & Shaw, A. T. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.222 · Cited by 51
McKay, R., Haider, B., Duh, M. S., Valderrama, A., Nakabayashi, M., Fiorillo, M., Ristovska, L., Wen, L., & Kantoff, P. (2017) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2017.4 · Cited by 49
Self-citationIdzerda, L., Rader, T., Tugwell, P., & Boers, M. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.131308 · Cited by 47
Mehta, A. R., & Armstrong, A. J. (2016) · Therapeutic Advances in Urology · doi:10.1177/1756287215603558 · Cited by 41
McManus, H. D., Dorff, T., Morgans, A. K., Sartor, O., Shore, N., & Armstrong, A. J. (2025) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-024-00906-z · Cited by 32
“Despite treatment, patients often experience disease progression while maintaining castrate levels of serum testosterone, either with metastases (metastatic castration-resistant PC [CRPC]; mCRPC) or without metastases (non-metastatic/M0 CRPC) [6].”
Joshua, A. M., Armstrong, A., Crumbaker, M., Scher, H. I., de Bono, J., Tombal, B., Hussain, M., Sternberg, C. N., Gillessen, S., Carles, J., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.04.005 · Cited by 28
Self-citationMcHugh, D., Eisenberger, M., Heath, E. I., Bruce, J., Danila, D. C., Rathkopf, D. E., Feldman, J., Slovin, S. F., Anand, B., Chu, R., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00731-5 · Cited by 23
Self-citation
Metadata
- Authors
- Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., Petrylak, D., Kantoff, P., Basch, E., Kelly, W. K., Figg, W. D., Small, E. J., Beer, T. M., Wilding, G., Martin, A., & Hussain, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-03-01
- Volume
- 26
- Issue
- 7
- Pages
- 1148-1159
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2167331614
- Cited by
- 2,241
- References
- 33
- FWCI
- 69.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.